There are approximately 20,000 proteins in the human heart—and one of them, if administered as a drug, could help patients recover more quickly following a myocardial infarction.

So what, exactly, occurs inside the human heart during a myocardial infarction?

Researchers have found a link between myocardial injury and a higher risk of death among patients hospitalized in the United States for COVID-19.

Ticagrelor has been approved by the FDA for reducing the risk of a first heart attack or stroke in high-risk coronary artery disease (CAD) patients.

Verve Therapeutics, a healthcare company focused on improving cardiovascular outcomes through gene-editing technology, has raised $63 million in Series A2 financing.

Evolocumab is an effective treatment option for patients with a recent myocardial infarction (MI), according to new findings published in JAMA Cardiology.

Hospitals throughout the United States have reported that a general fear of COVID-19 has led to significant drops in patients presenting with heart attack symptoms and other cardiovascular issues.

Women are prescribed fewer drugs after a heart attack than men—and they are more likely to die afterward as a result of that disparity.